Moderna Therapeutics (MRNA) - מקדם חוב לטווח ארוך להון

Moderna, Inc. (MRNA) relies on a universal mRNA technology that creates the foundation for treating future epidemics. The company is implementing robotics and AI to automate chain synthesis and accelerate the path to clinical trials. The current metric stands at 0.18. This price chart demonstrates stagnation due to declining sales of COVID-related products, while the market awaits the commercial success of new cancer and viral therapies.

This indicator measures the proportion of long-term liabilities within the equity structure, allowing for an assessment of financial risk and the company's degree of dependence on external borrowing. By analyzing the history of financial leverage regarding long-term debt, an investor can see how the aggressive expansion of oncology and R&D staff to diversify the Moderna, Inc. (MRNA) portfolio affects the balance between borrowed funds and equity.